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ABSTRACT
The base excision repair DNA glycosylase MutY
homolog (MYH) is responsible for removing ade-
nines misincorporated into DNA opposite guanine
or 7,8-dihydro-8-oxo-guanine (8-oxoG), thereby pre-
venting G:C to T:A mutations. Biallelic germline
mutations in the human MYH gene predispose
individuals to multiple colorectal adenomas and car-
cinoma. We have recently demonstrated that hMYH
interacts with the mismatch repair protein hMSH6,
and that the hMSH2/hMSH6 (hMutSa) heterodimer
stimulates hMYH activity. Here, we characterize the
functional effect of two missense mutations (R227W
and V232F) associated with hMYH polyposis that lie
within, or adjacent to, the putative hMSH6 binding
domain. Neither missense mutation affects the phys-
ical interaction between hMYH and hMSH6. However,
hMYH(R227W) has a severe defect in A/8-oxoG bind-
ing and glycosylase activities, while hMYH(V232F)
hasreducedA/8-oxoGbindingandglycosylaseactiv-
ities. The glycosylase activity of the V232F mutant
can be partially stimulated by hMutSa but cannot be
restored to the wild-type level. Both mutants also fail
to complement mutY-deficiency in Escherichia coli.
These data define the pathogenic mechanisms
underlying two further hMYH polyposis-associated
mutations.
INTRODUCTION
Cells possess several repair pathways for dealing with the
many different types of lesions in DNA. Reactive oxygen
species (ROS) are the most prevalent source of DNA lesions
in aerobic organisms, and oxidative damage to DNA can result
in mutagenesis and lead to degenerative diseases. One of
the most abundant and highly mutagenic forms of oxidative
damagetoDNA is7,8-dihydro-8-oxo-guanine(8-oxoGorGO).
GO lesions are repaired primarily by the base excision repair
(BER) pathways. The human 8-oxoG glycosylase (hOGG1)
protein, a functional eukaryotic homolog of Escherichia coli
MutM, can remove both ring-opened purine lesions and muta-
genicGOadductsiftheyarepairedwithcytosines(1–4).When
C/GO is not repaired by hOGG1, adenines are frequently
incorporated opposite GO bases during DNA replication (5,6)
which, after a second round of replication, lead to G:C to T:A
transversion mutations (6–9). Both the human MutY homolog
(hMYH) and MutS homologs (hMSH2/hMSH6 or hMutSa)
are involved in defending against the mutagenic effects of
A/GO mispairs.
The mismatch repair (MMR) system enhances the ﬁdelity
of DNA replication and genetic recombination. Inherited
deﬁciencies in the human MMR genes cause hereditary non-
polyposis colorectal cancer, an autosomal dominant disorder
characterized by early-onset colorectal cancer and other
extra-colonic cancers, notably endometrial cancer and cancers
of the stomach, small bowel, ureter and renal pelvis (10). The
hMSH2protein forms a heterodimer with hMSH6 to recognize
base–base mispairs and short insertion-deletion loops or forms
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deletion loops [reviewed in (11–13)]. The MMR system
is also involved in repair of oxidative DNA damage, and
mouse embryonic stem cells carrying a defective Msh2 allele
accumulate oxidized bases in their DNA (14,15). Recently,
Msh2p/Msh6p of yeast Saccharomyces cerevisiae and
human hMSH2/hMSH6 have been shown to bind A/GO
mismatches (16,17).
The human homolog of bacterial MutY, hMYH, encodes a
DNA glycosylase that excises adenines misincorporated
opposite GO or G through the BER pathway [reviewed in
(18,19)], thereby preventing G:C to T:A transversions
(20–23). Germline mutations in the hMYH gene cause auto-
somal recessive colorectal adenomatous polyposis (‘hMYH
polyposis’), which is characterized by multiple adenomas,
some of which progress to cancer (24–28). Tumors from affec-
ted patients contain somatic G:C to T:A mutations in the
adenomatous polyposis coli (APC) gene, a key gene that con-
trols cellular proliferation in the colon. We have shown that
hMYH interacts with hMutSa via hMSH6 and that hMYH
activity is enhanced by hMutSa (29). These observations sug-
gest that hMSH6 and hMYH may cooperate with each other in
defending against the mutagenic effects of GO lesions (29).
In this report, we characterize the functional effect of two
pathogenic hMYH missense mutations (R227W and V232F)
that lie close to, or within, the putative hMSH6 binding
domain (29). We show that although neither of the missense
mutations affected binding to the hMSH2/hMSH6 complex,
both had impaired A/GO binding and glycosylase activities
and failed to complement MutY-deﬁciency in E.coli. These
results provide evidence that the characteristic patterns of
somatic G:C to T:A mutations found in colorectal
tumors from hMYH polyposis patients are due to a reduced
ability of mutant hMYH to recognize and repair A/GO
mismatches.
MATERIALS AND METHODS
hMYH missense mutations
R227W was identiﬁed in combination with G382D in a
42-year-old patient (patient C103) with four colorectal
adenomas and rectal cancer (30), and V232F was identiﬁed
in combination with Y165C in a 70-year-old male (patient 18)
with between 100 and 1000 colorectal polyps (27).
Bacteria
E.colimutY
 mutant strain PR70 (Su-lacZ X74galU galKSm
r
micA68::Tn10kan) was obtained from M. S. Fox. The strain
CC104 containing a lacZ mutation at residue 461 of
b-galactosidase and its derivative CC104 mutM::mini-kan
mutY::mini-Tn10 were obtained from J. H. Miller. DE3 lyso-
genic strains were constructed according to the procedures
described by Invitrogen.
Construction of the hMYH mutants
The hMYH gene in pGEX-4T-hMYH (31) was isolated as a
BamHI–XhoI digested fragment and transferred into pET21a
(Novagene)toobtaintheclonepET21a-hMYH.MutanthMYH
genes were constructed by site-directed mutagenesis of
pET21a-hMYH and pGEX-4T-2-hMYH. Complementary
oligonucleotides containing the appropriate mismatches
for R227W (679 C!T) and V232F (694 G!T) were designed
using the QuikChange Primer Design program (http://
labtools.stratagene.com/QC/QCprimers) (R227W, 50-GGCA-
ACGTAGCATGGGTGCTGTGCCGT-30 and 50-ACGGC-
ACAGCACCCATGCTACGTTGCC-30; V232F, 50-GGGT-
GCTGTGCCGTTTCCGAGCCATTGGTGCTG-30 and 50-
CAGCACCAATGGCTCGGAAACGGCACAGCACCC-30).
Site-directedmutagenesisreactionswerecarriedoutaccording
to the manufacturer’s instructions (Stratagene). The entire
hMYH open reading frame was sequenced to conﬁrm the
presence of the desired mutation and to ensure that no
unwanted mutations had been introduced.
Wild-type and mutant hMYH genes were transferred from
pET21a-hMYH into pGEV1 (obtained from M. Clore at NIH)
by PCR. PCRs were performed with the templates pET21a-
hMYH, pET21a-hMYH(R227W), pET21a-hMYH(V232F)
and the primers Chang 226 (50-GCTATCGCTAGCATGA-
CACCGCTCGTCTCCCGC-30) and Chang 398 (50-TATT-
CTCGAGCTGGGCTGCACTGTTGA-30). The PCR products
were digested with NheI and XhoI, ligated into the NheI–
XhoI-digested pGEV1 vector and expressed to produce fusion
proteins with streptococcal protein G (GB1 domain) at their
N-termini and a 6-His tag at their C-termini. The generated
plasmids were named pGEV-hMYH, pGEV-hMYH(R227W)
and pGEV-hMYH(V232F). A similar approach was used to
transfer the wild-type and mutant hMYH genes into pKK223-3
(Amersham Pharmacia) using the primers Chang 402
(50-GCCGAATTCATGACACCGCTCGTCTCCCGCCTG-30)
and ChangXMA-3-hMYH (50-TGCGTTCCCGGGTCACTG-
GGCTGCACT-30), to allow expression of untagged proteins
from the tac promoter. Products were digested with EcoR1
and XmaI before ligating into EcoR1–XmaI digested
pKK223-3 to generate plasmids pKK-hMYH, pKK-R227W
and pKK-V232F.
Protein expression and purification
Mutant and wild-type pGEV1-hMYH constructs were trans-
formed into E.coli PR70/DE3 (mutY mutant) cells containing
the pRARE2 vector (Novagen) to enhance the expression of
the hMYH protein. The cells were grown at 37 C in Luria–
Bertani (LB) medium containing appropriate antibiotics. The
host PR70/DE3 cell has a transposon insertion at the chromo-
somal mutY gene and does not have MutY activity. Protein
expression was induced at an OD600 of 0.6 by adding isopropyl
b-D-thiogalactoside (IPTG) to a ﬁnal concentration of 0.2 mM
and incubating at 20 C for a further 16 h before harvesting
the cells. Recombinant hMYH was detected by 10%
SDS–PAGE.
His-tagged hMYH fusion proteins were bound to nickel
agarose according to the manufacturer’s instructions (Qiagen
Inc., Valencia, CA). The cell extracts were incubated with the
beads at 4 C for 1 h. After washing with buffer N [50 mM
potassium phosphate (pH 8.0), 300 mM NaCl] containing
50 mM imidazole, bound proteins were eluted by increasing
imidazole concentration in buffer N to 250 mM. Partially
puriﬁedproteinswerevisualizedby10%SDS–PAGEandfrac-
tions containing hMYH were pooled, dialyzed with buffer A
[20 mM potassium phosphate (pH 7.4), 0.1 mM EDTA, 10%
glycerol, 0.5 mM DTT and 0.1 mM phenylmethlysulfonyl
ﬂuoride], divided into small aliquots and stored at  80 C.
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Cell paste from 0.5 ml of the culture was resuspended in0.1 ml
of cracking dye containing 60 mM Tris–HCl (pH 6.8), 10%
glycerol, 1% SDS, 1% b-mercaptoethanol, and 0.01% bromo-
phenol blue and boiled for 10 min. Cell lysates (30 ml) or
partially puriﬁed hMYH proteins (2 ml) were fractionated
by 10% SDS–PAGE and transferred to a nitrocellulose
membrane (32). The hMYH protein was detected by western
blotting with polyclonal antibodies against a polypeptide of
hMYH (residues 344–361). The antibody was afﬁnity puriﬁed
by binding to a peptide afﬁnity column and further puriﬁed by
absorption to a nitrocellulose membrane containing immobil-
ized C-terminal hMYH. The membrane was subjected
to the enhanced chemiluminescence analysis system from
Amersham Pharmacia International according to the manufac-
turer’s protocol. To estimate the concentrations of partially
puriﬁed GB1-hMYH, a western blot including known amounts
of GB1-tagged E.coli MutY was assayed with an antibody to
annexin-2 (BD Bioscience, San Diego, CA) and quantitated.
GST–hMYH pull-down assay
GST–hMYH fusion proteins were immobilized on
glutathione–sepharose 4B (Amersham Parmacia) and incub-
ated with puriﬁed hMSH2/hMSH6 (hMutSa) heterodimers
as described previously (29). GST–hMYH–hMutSa com-
plexes were pelleted and detected by SDS–PAGE and western
blotting with antibodies against hMSH6 (BD Biosciences).
Concentrations of mutant and wild-type proteins bound to
beads were estimated from Coomassie-stained gels, and
similar levels of all GST–hMYH proteins in the assay were
conﬁrmed by western blotting with antibodies against hMYH.
Oligonucleotide substrates
The DNA substrates used in this study were
44mer 50 AATTGGGCTCCTCGAGGAATTA-
GCCTTCTGCAGGCATGCC 30
30 CCCGAGGAGCTCCTTAAY-
CGGAAGACGTCCGTACGGGGCC 50
20mer 50 CCGAGGAATTXGCCTTCTG 30
30 GCTCCTTAAYCGGAAGACG 50
(where X = A or C and Y = G or GO).
Thetopstrandwaslabeledatthe50 endwith[g-
32P]ATPand
polynucleotide kinase and was then annealed with the bottom
strand. The single-stranded overhangs were ﬁlled in with the
Klenow fragment of DNA polymerase I and unlabeled deoxy-
nucleotide triphosphates as described by Lu et al. (33).
Radioactive-labeled 20mer and 44mer DNA substrates were
usedforgelmobilityshiftandglycosylaseassays,respectively.
hMYH glycosylase activity assay
The glycosylase assay was carried out in a 10 ml reaction vol-
ume containing 25 mM HEPES (pH 7.0), 5 mM EDTA, 1.5%
glycerol, 50 mM ZnCl2, 1.8 fmol of
32P-labeled 44mer duplex
DNA containing an A/GO mismatch and partially puriﬁed
hMYH. The reaction was incubated at 37 C for 1.5 h before
adding 2 ml of 1 M NaOH and incubating at 90 C for 30 min.
Samples were lyophilized, resuspended in 3 ml formamide dye
(90% formamide, 10 mM EDTA, 0.1% xylene cyanol and
0.1% bromophenol blue) and heated to 90 C for 2 min before
loading onto a 14% polyacrylamide gel containing 7 M urea.
hMYH-DNA binding assay
The ability of hMYH to bind A/GO containing DNA was
assayed by gel retardation as described by Lu (34) with
some modiﬁcations. The reaction mixture contained 10 mM
Tris–HCl (pH 7.6), 0.5 mM DTT, 0.5 mM EDTA, 1.5%
glycerol, 20 ng poly(dI–dC) with 1.8 fmol
32P-labeled
20mer duplex DNA (29) and partially puriﬁed hMYH in a
total volume of 20 ml. After incubation at 37 C for 30 min, the
reaction was supplemented with 2 ml of 50% glycerol and
analyzed on a 6% polyacrylamide gel in 50 mM Tris borate
(pH 8.3), 1 mM EDTA and 2.5% glycerol.
Measurement of mutation frequency
Mutant and wild-type pKK223-3-hMYH constructs were
transformed into E.coli CC104mutYmutM and single colonies
cultured in LB medium. Protein expression was induced at
OD600 0.6 by adding IPTG at a ﬁnal concentration of 0.2 mM
and incubating at 20 C for a further 16 h. Four independent
overnight cultures were plated on both LB agar (10
 6 dilution)
and LB agar containing 0.1 mg/ml rifampicin (Rif). The muta-
tion frequency was calculated from the ratio of the colony
number on the Rif-plate (Rif-resistant, Rif
R) to the colony
number on the LB plate (total viable cells). The averages
and standard deviations were obtained from more than three
experimental data.
RESULTS
Wild-type and mutant hMYH physically interact
with hMSH6
We have previously deﬁned the hMSH6 binding domain
to residues 232–254 in hMYH (Figure 1) (29). Two hMYH
missensemutations(R227WandV232F)havepreviouslybeen
characterized in patients with hMYH polyposis (27,30) and
lie close to, or within, the hMSH6 binding domain (Figure 1).
Figure 1. EvolutionaryconservationoftheputativehMSH6bindingdomainin
hMYH and the mutationsanalyzed in this study. Alignmentof human(hMYH,
U63329), mouse (mMYH, AY007717), fission yeast (SpMYH, AF053340),
E.coli (EcMutY, P17802) and B.stearothermophilus (BsMutY, 1RRQ_A)
MYH homologs was carried out using Clustal W (v.1.7). The putative
hMSH6 binding domain is marked by a line and the highly conserved
residues are shaded. The hMYH missense mutations R227W and V232F are
atconservedandpartiallyconservedresidues,respectively(indicatedbystars).
The conserved Asp at the active center of the glycosylases is marked by an
arrow. The secondary structural elements of BsMutY (46) are shown at the
bottom.
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defective in binding with hMSH2/hMSH6 (hMutSa) using
glutathione S-transferase (GST) pull-down assays. As shown
in Figure 2, wild-type GST–hMYH proteins immobilized
on glutathione sepharose beads could pull down hMutSa,
conﬁrming the physical interaction between the two proteins.
Both hMYH(R227W) and hMYH(V232F) retained their
ability to interact with hMutSa (Figure 2).
Impaired glycosylase activities of the hMYH(R227W)
and hMYH(V232F) proteins
To further characterize the hMYH(R227W) and
hMYH(V232F) mutant proteins, we expressed the proteins
as fusion proteins tagged by both streptococcal protein G
(GB1 domain) and 6-His in an E.coli PR70/DE3/pRARE host.
The GB1 domain increased the solubility of hMYH and the
His-tag allowed afﬁnity puriﬁcation. The plasmid pRARE
contains rare tRNA genes for improved hMYH protein trans-
lation. After passing through a nickel-agarose column, the
partially puriﬁed hMYH proteins (2 m1) were applied to 10%
SDS–PAGE for Coomassie blue staining and western blotting
against hMYH to determine their purity and concentrations
(Figure 3A and B). hMYH proteins were partially puriﬁed to
 15% homogeneity after passing through a nickel-agarose
column (Figure 3A). Surprisingly, the amounts of protein
indicated by western blotting were not proportional to that
indicated by Coomassie blue staining. There are two possib-
ilities for this discrepancy: (i) the band of the correct size for
GB1-hMYH probably contains other protein(s) and (ii) the
mutant and wild-type proteins do not react to the hMYH
antibody equally. Since the concentrations of partially puriﬁed
hMYH proteins cannot be precisely determined from the
Coomassie blue staining, we determined the amounts of pro-
teins by comparing them with known amounts of GB1-MutY
on western blotting (data not shown). The protein concentra-
tions of wild-type, hMYH(R227W) and hMYH(V232F) were
estimated to be 44, 32 and 59 mg/ml, respectively.
Glycosylase activities were assayed using a 44 bp duplex
containing an A/GO mismatch with partially puriﬁed proteins.
hMYH(R227W) protein had no detectable glycosylase
activity with A/GO mismatches (Figure 4A, lane 2), and
hMYH(V232F) displayed a reduced ability to excise adenine
(cleaving only 7% of the DNA substrates as compared with
55% by wild-type hMYH; Figure 4A, lanes 1 and 3). After
adjusting for the protein concentrations, hMYH(R227W) and
Figure 3. Analyses of hMYH mutant proteins. (A) Partially purified GB1-hMYH-His fusion proteins detected by Coomassie blue staining. Wild-type and mutant
proteinswereexpressedinE.coliPR70/DE3andpartiallypurifiedbynickel-agaroseaffinitychromatography.Analiquotof2m1ofeachproteinwasappliedto10%
SDS–PAGE for staining with Coomassie blue. (B) Partially purified GB1-hMYH-His fusion proteins detected by western blotting. Samples are similar to (A) but
detectedbywesternblottingwithpolyclonalantibodiesagainsthMYHresidues344–361purifiedbypeptideaffinitycolumn.(C)Expressionofwild-typeandmutant
hMYHproteinsinE.coliCC104mutYmutM.hMYHproteinsincelllysatesweredetectedbywesternblottingwithpolyclonalantibodiesagainsthMYHresidues344–
361purifiedbypeptideaffinitycolumnandmembrane-boundhMYH.Lane1,CC104 (mutYmutM);lanes2–5,CC104 (mutYmutM)expressingpKK223-3vector
alone,wild-typehMYH,hMYH(R227W)andhMYH(V232F),respectively.V232FmutanthMYHproteinwasexpressed 2-foldhigherthanthoseofwild-typeand
R227W hMYH proteins in vivo.
Figure 2. Physical interaction between hMutSa and wild-type and mutant
hMYH. Purified hMutSa (hMSH2/hMSH6 complex) pulled down by
GST–hMYH beads was fractionated by a 10% SDS–polyacrylamide gel fol-
lowed by western blot analysis using antibodies against hMSH6. Equivalent
concentrations of wild-type and mutant GST–hMYH proteins were used in the
assay.PurifiedhMutSa(0.2mg)wasappliedtolane1.Forcontrol,hMutSawas
applied to beads containing GST alone (lane 2). Wild-type, hMYH(R227W)
and hMYH(V232F) all bound strongly to hMutSa.
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sylase activity toward A/GO-containing DNA substrates.
DNA-binding affinities of mutant hMYH proteins
Using gel retardation assays, we compared the A/GO-DNA
binding activities of hMYH(R227W) and hMYH(V232F)
with wild-type hMYH. Three DNA–protein complexes were
observedwith the taggedwild-type hMYH (Figure4B,lane 2),
two DNA–protein complexes were observed with the tagged
hMYH (V232F) (Figure 4B, lane 10) and only one DNA–
protein complex was observed with the tagged hMYH
(R227W) (Figure 4B, lane 6). To verify the speciﬁc complex
of hMYH with the A/GO substrate, binding reactions were
carried out with a
32P-labeled C/G-containing 20mer substrate
(Figure 4B, lanes 1, 5 and 9). Only one protein–DNA complex
was observed with the wild-type and mutant hMYH proteins
and its mobility is the same as that of the complex in the
hMYH (R227W) reaction but is different from the three
DNA–protein complexes observed with wild-type hMYH.
In addition, competitive binding experiments were performed,
in which
32P-labeled A/GO-containing DNA was incubated
with a 50-fold excess of unlabeled A/GO and C/G substrates.
All three DNA–protein complexes observed with wild-type
hMYH (Figure 4B, lane 3) and the upper band in binding
reaction of hMYH(V232F) (Figure 4B, lane 11) were weak-
ened upon the addition of excess unlabeled A/GO substrate.
The unlabeled homoduplex (C/G 20mer) had little effect on
the hMYH binding to labeled A/GO substrate (Figure 4B,
lanes 4 and 12). Thus, the three DNA–hMYH complexes
observed with wild-type hMYH appear to be speciﬁc (marked
with Y-DNA, S1 and S2 complexes). The DNA–protein
complex shown in the hMYH (R227W) binding reactions and
thelowerDNA–proteincomplexinthehMYH(V232F)binding
reactions were not changed by adding either excess unlabeled
A/GO-containing DNA or C/G homoduplex (Figure 4B,
lanes 7, 8, 11 and 12). Therefore, this complex is non-
speciﬁc (marked by NS). For binding capacity of the mutant
hMYH proteins, only the top complex (marked by Y-DNA)
was taken into consideration. Approximately 12% of the DNA
substrates were bound by the wild-type enzyme (Figure 4B,
lane 2); the hMYH (R227W) protein exhibited no DNA bind-
ing toward A/GO mismatches (Figure 4B, lane 6); and hMYH
(V232F) has an A/GO DNA-binding activity (Figure 4B,
lane 10)  2% compared with the wild-type enzyme.
The glycosylase activities of wild-type hMYH and
V232F hMYH can be stimulated by hMutSa
We have previously shown that the binding and glycosylase
activities of hMYH with A/GO mismatch are enhanced by
hMutSa (30). Because the hMYH missense mutants (R227W
and V232F) can physically interact with hMutSa (Figure 2),
we examined whether their function can be stimulated by
hMutSa. When wild-type hMYH (10 nM) was supplemented
with hMutSa (0.25 or 2 nM) in the glycosylase reactions,
we observed a 2.4-fold increase of glycosylase activity
(Figure 5, lanes 1–3). However, no glycosylase activity was
restored to the hMYH(R227W) mutant (109 nM) by adding
hMutSa (Figure 5, lanes 4–6). The glycosylase activity of
Figure 4. (A) Glycosylase activities of partially purified GB1-hMYH-His mutants. Lane 1, wild-type (WT) hMYH; lane 2, hMYH(R227W); and lane 3,
hMYH(V232F). 50 end labeled 44mer DNA duplex (1.8 fmol) containing an A/GO mismatch was incubated with partially purified wild-type (48 ng), R227W
(32ng)andV232F(59ng)GB1-hMYHfor1.5hat37 CbeforecleavageofthephophodiesterbackbonebyNaOH.Thereactionproductswerefractionatedona14%
polyacrylamide sequencing gel containing 7 M urea. Data presented are a PhosphorImager image. (B) DNA-binding activities of GB1-hMYH mutants.
The
32P-labeled DNA (20mer) containing the C/G base pair (lanes 1, 5 and 9) and A/GO mismatch (lanes 2–4, 6–8 and 10–12) were incubated with partially
purified wild-type (48 ng), R227W (32 ng) and V232F (59 ng) GB1-hMYH at 37 C for 30 min, and products were run on non-denaturing 6% polyacrylamide gels.
Lanes1–4,5–8and9–12arereactionsperformedwithhMYH(WT),hMYH(R227W)andhMYH(V232F),respectively.Lanes3,7and11containa50-foldexcessof
unlabeledA/GO-DNA(competitor)inadditiontothelabeledsubstrate.A50-foldexcessofunlabeledhomoduplex(C/G-DNA)wasaddedtolanes4,8and12.Data
presented are a PhosphorImager image.The arrows mark the majorspecific hMYH–DNAcomplex (Y-DNA),two minor specifichMYH–DNAcomplexes (S1 and
S2), non-specific protein–DNA complex (NS) and free DNA substrate (free).
Nucleic Acids Research, 2005, Vol. 33, No. 2 601hMYH(V232F) mutant protein (40 nM) could be partially
stimulated by hMutSa (Figure 5, lanes 7–9), but could not
be restored to the wild-type level.
The reaction conditions under which we observe hMYH
binding to A/GO mismatches in the presence of hMutSa
contain 30 mM NaCl and use 44mer DNA (30). Under these
conditions, the non-speciﬁc protein–DNA complex (NS)
(Figure 4B) is more dominant. We were unable to detect
signiﬁcant enhancement of A/GO-DNA binding activity of
partially puriﬁed GB1- and His-tagged hMYH by hMutSa
(data not shown).
In vivo complementation activity of the hMYH(R227W)
and hMYH(V232F) mutants
E.coli cells with a single mutation in mutY or mutM genes are
moderate mutators; however, the mutYmutM double mutant is
a strong mutator because it fails to remove GO lesions and
correct replication errors (35,36). In the absence of functional
MutY and MutM, a high level of mutations in the Rif-binding
site of RNA polymerase renders the cell resistant to Rif.
To study the in vivo complementation activity of the
hMYH(R227W) and hMYH(V232F) mutants, the mutant
genes were expressed under the control of the tac promoter
as untagged proteins in CC104mutYmutM cells. Western blot
analysis revealed that V232F mutant hMYH protein
(Figure 3C, lane 5) was expressed  2-fold higher than those
of wild-type and R227W hMYH proteins (Figure 3C, lanes 3
and 4). CC104mutYmutM cells with vector pKK223-3 had a
lower mutation frequency than the cells without the vector
(Table 1, compare rows 2 and 3), the reason for this is unclear,
although we have seen this anomaly before (37). Expression of
wild-type hMYHsigniﬁcantly lowered the mutationfrequency
in E.coli CC104mutYmutM (Table 1, compare rows 3 and 4)
(P < 0.007); however, the expression of hMYH(R227W)
mutant protein did not (Table 1, compare rows 3 and 5).
Expression of hMYH(V232F) reduced the mutation frequency
slightly, but not signiﬁcantly (P < 0.17) (Table 1, row 6), when
compared with vector alone (Table 1, row 3).
DISCUSSION
ROS are the most prevalent source of DNA lesions in aerobic
organisms, and mammalian cells have developed several
repair pathways to cope with the resultant oxidative DNA
damage. The BER protein hMYH is essential in protecting
against such damage and inherited defects in hMYH pre-
dispose to colorectal tumors in humans (24–28). Furthermore,
although Myh knockout mice are cancer-free (38,39); com-
bined Myh and Ogg1—deﬁciency predisposes mice to lung
and ovarian tumors and lymphomas (40). In this study, we
have conﬁrmed a direct interaction between hMSH2/hMSH6
and hMYH and provide further support that a reduced ability
of mutant hMYH to recognize and repair A/GO mismatches
underlies the mechanism of pathogenesis in hMYH polyposis.
Additional studies are now warranted to determine whether
disruption of the hMYH–hMSH6 interaction and/or uncoup-
ling of the MMR and BER pathways also contributes to colo-
rectal tumourigenesis.
To date, the biochemical effects of only the two most com-
mon hMYH mutations in Caucasians, Y165C and G382D,
have been deﬁned (41–43). The Y165C of hMYH and the
equivalent Y82C of E.coli MutY are defective in DNA glyco-
sylase activity, while hMYH(G382D) expressed in E.coli
is inactive (43) and the equivalent EcMutY(G253D) is only
partially inactive (41,42). Here, we show that two additional
variants of hMYH (R227W and V232F) associated with
hMYH polyposis are also functionally compromised, although
both retain the ability to physically interact with hMSH6.
Similar to the Y165C mutation (43), the R227W mutation
severely reduces the ability of hMYH to bind an A/GO mispair
and catalyze adenine excision from A/GO mismatches.
In addition, the R227W mutant also displays an impaired
function to complement the phenotype of E.coli mutY.
hMYH(V232F) is also deﬁcient in DNA binding and glyco-
sylase activities, although the biochemical differences
between the mutant and wild-type enzymes are less pro-
nounced than for hMYH(R227W). The glycosylase activity
Figure 5. Functional interaction between hMutSa and wild-type and mutant
hMYH proteins. The glycosylase assay was performed as in Figure 4A, except
that the reactions contained different amounts of hMYH proteins and 0.25 or
2 nM of hMutSa. Lane 1–3, reactions contained 10 nM of wild-type hMYH
with 0, 0.25 and 2 nM of hMutSa, respectively; lanes 4–6, reactions contained
109 nM of hMYH(R227W); and lanes 7–9, reactions contained 40 nM of
hMYH(V232F). The arrows indicate the intact DNA substrate and nicked
product.
Table 1. Mutation frequencies of mutYmutM E.coli expressing mutant
hMYH proteins
Strains
a Mutation
frequency
b of Rif
R
colonies/10
8 cells
Increase
(fold)
c
CC104+ (wild type) 0.7 – 0.2 1
CC104  (mutYmutM) 667 – 48 953
CC104 /pKK223-3 (vector) 223 – 28 319
CC104 /pKK-hMYH (wild type) 142 – 29 203
CC104 /pKK-R227W (mutant) 272 – 68 389
CC104 /pKK-V232F (mutant) 187 – 36 267
aE.coli strains CC104+ and CC104  contain wild-type and mutated mutY and
mutM genes, respectively.
bThe in vivo activities of wild-type and mutant hMYH were measured by
the frequency of Rif-resistant colonies (average of at least three separate
experiments, with errors reported as the standard deviations).
cFold increase compared with the wild-type strain.
602 Nucleic Acids Research, 2005, Vol. 33, No. 2of the V232F mutant can be partially stimulated by hMutSa
but cannot be restored to the wild-type level. This mutant
enzyme may be able to recognize mispairs and catalyze
some reactions as observed for the human G382D homolog
(44). This could result in the ‘partially repaired’ site being
exposed to inappropriate and potentially mutagenic activities
by enzymes, such as hOGG1 (44).
The deleterious effects of the R227W and V232F mutations
in hMYH polyposis may be explained by the bacterial MutY
structures (45,46). Both R227and V232 are located at an alpha
helix containing the conserved Asp at the active center
(Figure 1). The R227 residue of hMYH is conserved in the
MutY family, and the corresponding residues of E.coli and
Bacillus stearothermophilus MutY are R143 and R149,
respectively (Figure 1). According to the recent X-ray struc-
ture of BsMutY–DNA complex (46), this conserved Arg is
within 3A ˚ to the phosphate group 50 to the mismatched aden-
ine. A mutation of this conserved Arg to Trp will decrease the
positive charge and may affect the interaction between
MutY and DNA by reducing their electrostatic interaction.
The Val232 residue of hMYH is less conserved in the
MutY family and the corresponding residues of E.coli and
B.stearothermophilus MutY are Cys148 and Leu154, respect-
ively (Figure 1). Cys148 of EcMutY (45) and Leu154 of the
BsMutY–DNA complex (46) are within 4A ˚ to the iron–sulfur
cluster which is ligated by four conserved cysteines. The
residues spacing the four conserved cysteines are dominated
by positively charged amino acids and are important for sub-
strate recognition. The bulky side chain of the substituted Phe
in V232F may disrupt the proper alignment of the iron–sulfur
cluster loop and thus affect DNA binding and catalysis.
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